Search results
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters· 4 days ago, opens new tab blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. In the wake of February's U.S. Food and Drug Administration ...
Israel stocks higher at close of trade; TA 35 up 0.50% By Investing.com
Investing.com· 10 hours agoIsrael stocks higher at close of trade; TA 35 up 0.50%
Teva stock gains on trial win, Q1 beat (NYSE:TEVA)
Seeking Alpha· 5 days agoTeva Pharmaceutical (TEVA) stock posts record gains due to better-than-expected Q1 revenue and positive Phase 3 trial results for its schizophrenia drug....
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Benzinga· 5 hours agoPfizer Inc PFE is looking to build on the success of its COVID-19 vaccine rollout by introducing a...
How sham patents are hurting the pharma industry
Pharmaceutical Technology via Yahoo Finance· 7 days agoAfter a patent expires, other pharmaceutical companies are free to manufacture the drug as a generic or biosimilar. This encourages competition, making...
Cuba may import sugar, rum industry pressed amid disastrous harvest
Reuters via Yahoo News· 4 days agoThe Cuban sugar harvest is winding down at the lowest tonnage since 1900, forcing the government to...
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing -...
Benzinga· 3 days agoPharmaceutical companies have been at the forefront of artificial intelligence for quite some time....
Teva Pharm Q1 profit misses estimates, revenue risea
WHTC 1450 Holland· 5 days agoBy Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales ...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters via Yahoo Finance· 6 days agoTeva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's...
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
Simply Wall St. via Yahoo Finance· 6 days agoMay 8th 2024 Pliant Therapeutics Earnings Insights Looking ahead, revenue is forecast to grow 67%...
